Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion

Yohannes Tesfaigzi , Paula Meek , Suzanne Lareau
{"title":"Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion","authors":"Yohannes Tesfaigzi ,&nbsp;Paula Meek ,&nbsp;Suzanne Lareau","doi":"10.1016/j.cair.2006.02.001","DOIUrl":null,"url":null,"abstract":"<div><p>Chronic obstructive pulmonary disease (COPD) exacerbations are an important cause of the considerable morbidity and mortality found in COPD. COPD exacerbations increase with increasing severity of COPD, and some patients are prone to frequent exacerbations leading to hospital admission and readmission. These frequent exacerbations may have considerable impact on quality of life and activities of daily living. Factors that increase the risk for COPD exacerbations are associated with increased airway inflammation caused by common pollutants and bacterial and/or viral infections. These inflammatory responses cause mucus hypersecretion and, thereby, airway obstruction and associated exacerbations. While chronic mucus hypersecretion is a significant risk factor for frequent and severe exacerbations, patients with chronic mucus hypersecretion have a lower rate of relapse after initial treatment for acute exacerbation. The benefit of antibiotics for treatment of COPD exacerbations is small but significant. While the mechanisms of actions are not clear, mucolytic agents reduce the number of days of disability in subjects with exacerbations. Reducing mucous cell numbers in small airways could be a useful way to reduce chronic mucus hypersecretion. Our studies suggest that programmed cell death is crucial in the resolution of metaplastic mucous cells, and understanding these mechanisms may provide novel therapies to reduce the risk of COPD exacerbations.</p></div>","PeriodicalId":89340,"journal":{"name":"Clinical and applied immunology reviews","volume":"6 1","pages":"Pages 21-36"},"PeriodicalIF":0.0000,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cair.2006.02.001","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and applied immunology reviews","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1529104906000201","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

Abstract

Chronic obstructive pulmonary disease (COPD) exacerbations are an important cause of the considerable morbidity and mortality found in COPD. COPD exacerbations increase with increasing severity of COPD, and some patients are prone to frequent exacerbations leading to hospital admission and readmission. These frequent exacerbations may have considerable impact on quality of life and activities of daily living. Factors that increase the risk for COPD exacerbations are associated with increased airway inflammation caused by common pollutants and bacterial and/or viral infections. These inflammatory responses cause mucus hypersecretion and, thereby, airway obstruction and associated exacerbations. While chronic mucus hypersecretion is a significant risk factor for frequent and severe exacerbations, patients with chronic mucus hypersecretion have a lower rate of relapse after initial treatment for acute exacerbation. The benefit of antibiotics for treatment of COPD exacerbations is small but significant. While the mechanisms of actions are not clear, mucolytic agents reduce the number of days of disability in subjects with exacerbations. Reducing mucous cell numbers in small airways could be a useful way to reduce chronic mucus hypersecretion. Our studies suggest that programmed cell death is crucial in the resolution of metaplastic mucous cells, and understanding these mechanisms may provide novel therapies to reduce the risk of COPD exacerbations.

Abstract Image

慢性阻塞性肺疾病加重和慢性粘液分泌过多
慢性阻塞性肺疾病(COPD)恶化是COPD患者发病率和死亡率较高的一个重要原因。COPD加重随着COPD严重程度的增加而增加,一些患者容易频繁加重导致住院和再入院。这些频繁的恶化可能对生活质量和日常生活活动产生相当大的影响。增加COPD恶化风险的因素与常见污染物和细菌和/或病毒感染引起的气道炎症增加有关。这些炎症反应引起粘液分泌过多,从而引起气道阻塞和相关的恶化。慢性粘液分泌过多是频繁和严重恶化的重要危险因素,慢性粘液分泌过多的患者在初始治疗急性恶化后复发率较低。抗生素治疗慢性阻塞性肺病加重的益处虽小,但意义重大。虽然作用机制尚不清楚,但黏液溶解剂可减少急性发作患者的残疾天数。减少小气道粘液细胞数量可能是减少慢性粘液分泌过多的有效方法。我们的研究表明,程序性细胞死亡在化生黏液细胞的溶解中至关重要,了解这些机制可能为降低COPD恶化风险提供新的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信